HK Stock Market Move | CARSGEN-B(02171) rose nearly 5% in morning trading. Self-developed product KJC2219 has initiated clinical trials in China.

CARSGEN-B(02171) rose nearly 5% in early trading, up 3.84% to HK$9.46 as of press time, with a trading volume of HK$18.8551 million. In terms of news, Koji Pharmaceuticals announced that the company has initiated a clinical trial in China for its self-developed universal CAR-T cell therapy candidate product KJ-C2219 targeting the CD19/CD20 dual antigen for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. KJ-C2219 is developed on the THANK-u Plus platform and is planned to be used for the treatment of hematologic malignancies and autoimmune diseases. Additionally, Koji Pharmaceuticals disclosed that the Phase II clinical trial CT041-ST-01 (NCT04581473) has produced positive results. The trial is a randomized, multicenter clinical trial conducted in China to evaluate the efficacy and safety of Shurjio Lungwei Injection (R&D code: CT041, a targeted Claudin18.2 autologous CAR-T cell candidate product) for the treatment of advanced gastric/esophageal junction adenocarcinoma with positive Claudin18.2 expression who have previously failed at least second-line treatment. Subjects were randomly assigned in a 2:1 ratio to Shurjio Lungwei Injection group or investigator-selected treatment group (including paclitaxel, docetaxel, irinotecan, apatinib, or nivolumab).